Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, Bernard, Wanner, Christoph, Lachin, John M., Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Mattheus, Michaela, Devins, Theresa +4 more·2015·New England Journal of Medicine

DOI 10.1056/nejmoa1504720

Cited by (12,156)

Items 12,101–12,156 of 12,156

An individual patient meta-analysis assessed the associations between change in albuminuria and acute changes in the glomerular filtration rate in randomized controlled trials of chronic kidney disease progression
Lesley A. Inker, Hiddo JL Heerspink, Hocine Tighiouart, Shiyuan Miao, Juhi Chaudhari, Lucia Del Vecchio, Jürgen Floege, Thierry Hannedouche, Enyu Imai, Tazeen H. Jafar et al. · 2026 · Kidney International
Patterns of Evidence-Based Medication Use in Older Adults with Chronic Heart Failure in Slovakia: A Population-Based Study Using the National Health Information Center Database
Martin Wawruch, Mariana Mrazova, Viktor Foltin et al. · 2026 · Drugs & Aging
SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications
Xue-Ting Zheng, Hui-Yi Xie, Xiu-Heng Wang, Yue Zhao, Jia-Yan Yang, Yun-Xi Liu, Xian-Liang Yuan, Hui-Fang Tang, Zhisheng Jiang, Heng-Jing Hu · 2026 · Molecular Biomedicine
Effects of SGLT ‐2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine‐N‐Oxide in Patients With Type‐2 Diabetes
Katja B. Zimmer, Arne Gessner, Dennis Kannenkeril, Agnes Bosch, Armin Ströbel, Roland Erich Schmieder, Renke Maas · 2026 · Endocrinology Diabetes & Metabolism
Mechanisms of anemia in patients with chronic kidney disease and involvement of cardiorenal anemia syndrome
Shoichiro Daimon · 2026 · Renal Replacement Therapy
Empagliflozin Improves Angina and Endothelial Dysfunction Indices in Angina and No Obstructive Coronary Arteries (ANOCA)
Danielle N. Tapp, Sukhleen Kaur, Olga Toleva, Paxson Tipler, Namrita D. Ashokprabhu, Pooja Acharya, Christian W. Schmidt, Leslie L. Korbee, Michelle S. Hamstra, Michael Tranter et al. · 2026 · Arteriosclerosis Thrombosis and Vascular Biology
Genitourinary safety aspects of SGLT2 inhibitor therapy in patients with type 2 diabetes
Л. А. Суплотова, A.S. Kokin, Alyona A. Golubeva · 2026 · Diabetes Mellitus
PAD as a Marker of Systemic Atherosclerosis: A Comprehensive Review of Residual Risk and Contemporary Strategies for MACE and MALE Reduction
Giuseppe Miceli, Maria Grazia Basso, M. Cuffaro, Antonino Marchese, Antonino Tuttolomondo · 2026 · Medicina
SGLT2 inhibitors in cardiology, nephrology, and diabetes care: who should take them, how to start treatment, and when to discontinue
Jan Škrha · 2026 · Vnitřní lékařství
The role of SGLT2 inhibitors in outpatient cardiology practice
Petra Buděšínská · 2026 · Vnitřní lékařství
Emerging Therapies in Diabetes: New Drugs and Innovative Remedies
Patel Pankti bhavikkimar, Amar M. Raval, Helly Bhupendrabhai Patel, Krisha Hiteshbhai Patel, Poorv Patel, Tushar Prajapati · 2026 · Pharmacology and Toxicology Research
Comorbid Cardiovascular-Liver Disease Disparities: Current Understanding and Future Directions
Abdelrahman H. Hafez, Mohamed Nour, Ramzi Ibrahim, Jenna Othman, Mohamed Reyad Mohamed, Kamal Awad, Julia Zanco, Vinicius De Sousa Barzon Serra, Mahmoud Abdelnabi, Mahmoud Elbsiony et al. · 2026 · Current Cardiology Reports
Centrally administered SGLT2 inhibitor improves gut barrier function through the brain orexin, AMPK, dopamine D2 signaling and the vagal pathway in rats
Takuya Funayama, Tsukasa Nozu, Masatomo Ishioh, Chihiro Sumi, Mayumi Hatayama, Masayo Yamamoto, Motohiro Shindo, Shuichiro Takahashi, Toshikatsu Okumura · 2026 · Neuroscience Research
Impact of Empagliflozin on mRNA Levels of Cardiotrophin-1 and GDF-15 in Patients with Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Double-Blind Pilot Trial
Reza Rastgoo Sisakht, Mahnaz Yousefi Ramandi, Fereshteh Ebrahimi · 2026 · Journal of Cardiovascular and Thoracic Research
SGLT2 Inhibitors’ Effects on Biomarkers of Myocardial Injury: A Systematic Review
Elnaz Khani, Naser Aslanabadi, Haleh Rezaee · 2025 · Journal of Cardiovascular and Thoracic Research
Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular–Kidney–Metabolic Disease: A Narrative Review
Boknyun Kim, Joseph Kim, Grace Kim, Kitai Kim · 2026 · Pharmaceuticals
Screening Strategies for Silent Myocardial Ischemia in Individuals With Diabetes Without Known Coronary Artery Disease: Systematic Review and Meta‐Analysis
Vanessa del Carmen Romero Martínez, Juan Pablo Tobón Cuenca, PAULA ALEJANDRA LONGAS GARCIA, Luis Eduardo Salazar Moreno, Ginés Sanz Romero · 2026 · Clinical Cardiology
Inhibidores del cotransportador sodio-glucosa tipo 2 en la insuficiencia cardíaca: revisión sistemática
Jimmy Raúl Villarroel-Casco, Janela Victoria Ramírez-Carvajal, Jesseña Abigail Reisancho-Tenelema, Evelyn Alexandra Encalada-Bermeo · 2026 · Sanitas. Revista arbitrada de ciencias de la salud.
Cost-effectiveness of early empagliflozin initiation after acute myocardial infarction: a German statutory health insurance perspective
Priyanka Boettger, Eleni S. Nakou, Thomas Kinsley, Michael Buerke, Eva‐Maria Wild, Samuel Tobias Sossalla · 2026 · Cost Effectiveness and Resource Allocation
Benzothiazole-Derived Compounds as Potential Drugs for the Treatment of Type 2 Diabetes: A Descriptive Review
Ana María Correa-Basurto, Miguel Ángel Serra Valdés, Laura Cristina Cabrera Pérez, Natalia Reyes-Vallejo, Alejandro Cruz, Martha Cecilia Rosales‐Hernández, J. A. SALAZAR, Jessica Elena Mendieta‐Wejebe · 2026 · International Journal of Molecular Sciences
Metabolic memory in diabetic complications: evidence for persistent cellular states and limits of therapeutic reversal
Yulan Cai, Shuangyu He, Feng Zeng, Chuyu Liu · 2026 · Frontiers in Endocrinology
Implementation of guideline-directed cardioprotective therapy in patients living with type 2 diabetes in outpatient cardiology ambulatory setting: the Italian CardioMET registry
Paola Gargiulo, Federica Marzano, Laura Liccardi, Savina Nodari, Matteo Cameli, Francesco Giallauria, Federico Guerra, Egidio Imbalzano, Gianfranco Sinagra, Stefano Carugo et al. · 2026 · European Journal of Internal Medicine
Type 2 Diabetes and Central Obesity in the Cardiovascular Kidney–Metabolic Continuum: A Critical Narrative Review
Dini Aulia Cahya, Shod Abdurrachman Dzulkarnain, Billy Jordan Wrahatnala, Merika Soraya, Endang Sri Wahjuni · 2026 · Biomedical & Pharmacology Journal
Dapagliflozin and ventricular repolarization across heart failure phenotypes
Gülüzar Traş, Fuat Polat, Melike Saday Bozkurt · 2026 · Current Medical Research and Opinion
Endothelial and oxidative biomarker profiles in atrial fibrillation according to SGLT2 inhibitor exposure: a cross-sectional study
Łukasz Wołowiec, Joanna Banach, Michał Janiak · 2026 · Research Square
Navigating medical management in chronic coronary syndrome: evidence, controversies and guideline updates
Rodney Yu-Hang Soh, Aaron Kwun Hang Ho, Gavin Ng, Ching-Hui Sia, William Kok-Fai Kong, Ng Kwan Lee, Poay-Huan Loh, Tiong-Cheng Yeo, Swee-Chye Quek, Huay-Cheem Tan et al. · 2026 · Singapore Medical Journal
SGLT2 Inhibitors and Asthma Exacerbation Risk Among Patients With Type 2 Diabetes and Asthma: A Target Trial Emulation
Kevin Yi‐Chen Liao, Daniel Hsiang‐Te Tsai, Michael Chun‐Yuan Cheng · 2026 · Clinical Pharmacology & Therapeutics
Diretriz Brasileira de Insuficiência Cardíaca – 2026
Marcus Vinı́cius Simões, Lídia Zytynski Moura, Sílvia Marinho Martins, Ricardo Mourilhe‐Rocha, Luiz Cláudio Danzmann, José Albuquerque de Figueiredo Neto, Fabiana G. Marcondes‐Braga, Múcio Tavares de Oliveira, Denílson Campos de Albuquerque, Aguinaldo Figueiredo Freitas et al. · 2026 · Arquivos Brasileiros de Cardiologia
Cardiovascular Outcome Evidence in ANVISA Approved Professional Prescribing Information for SGLT2 Inhibitors
Kitete Tunda Bunnel, André Oliveira Baldoni, Raldner Borges e Reges · 2026 · Research Square
Targeting Metainflammation in Hidradenitis Suppurativa: The Emerging Role of GLP-1 Receptor Agonists and Metabolic Pharmacotherapies
Emma Brogaard, Simon Francis Thomsen · 2026 · Targets
Empagliflozin as a Method for Correcting Endothelial Dysfunction in Rats Fed a High-Fat Diet
G. T. Ivanova · 2026 · Journal of Evolutionary Biochemistry and Physiology
Diagnosis and evaluation of obesity for therapeutic selection
Marcio L. Griebeler, Bartolome G. Burguera, Dua Al-Husni · 2026 · Advances in pharmacology
Evolution of risk management in diabetes mellitus: from standardized restrictions to personalized technological solutions
S. J. Qosimova · 2026 · Health care of Tajikistan
Prediction of Chronic Heart Failure Developmentin Patients with Diabetes and Atherosclerotic Complications: A Narrative Review
Saniya Siddiqua, Adeeba Ahmed, Christy Joy, Tarannum Naaz, Insha Ahmed, Akshita Bharadwaj · 2026 · International Journal of Modern Science and Research Technology
GLP‐1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications
Peter Ueda · 2026 · Journal of Internal Medicine
SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Propensity Score-Matched Cohort Study Comparing Adherence and Persistence with Specific Reference to Cardiovascular Disease
M. Asunción González-González, M. Aránzazu Pedrosa-Naudín, Diego Fernández‐Lázaro, Isabel Díaz Planelles, E. Alvarez, Eduardo Gutiérrez‐Abejón · 2026 · Pharmaceuticals
A study on flavanomarein as a potential natural SGLT2 inhibitor through molecular docking
Wanlin Che, Yaoqi Li, Rui Yan · 2026 · In Silico Research in Biomedicine
Diabetes‐Associated Cognitive Impairment: Pathophysiology and Emerging Therapies
Osman Corbali, Priyanka Menon, Halil Ibrahim Corbali, Ram Jagannathan, Allan I. Levey · 2026 · Annals of Clinical and Translational Neurology
Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of Current Evidence, Mechanisms, and Adverse Effects
Sam Woodworth, Robert Hayden · 2026 · Journal of Brown Hospital Medicine
Comparative Cardiorenal Efficacy and Safety of SGLT2 Inhibitors and Finerenone in Chronic Kidney Disease With Type 2 Diabetes: A Systematic Review and Network Meta‐Analysis
Fadi Alghzawi, Yousef Alghzawi, Leen Alhassan, Raghad Kiyyam · 2026 · Diabetes Obesity and Metabolism
ROS–NLRP3 Inflammasome Axis in Obesity: A Critical Review of Oxidative Stress-Driven Inflammation and Emerging Therapeutic Strategies
Sungeun Ahn, Sangmin Park, Shakina Yesmin Simu · 2026 · Medicina
Diabetes im Krankenhaus – Praxisempfehlung der DDG
Karsten Müssig, Baptist Gallwitz, Thomas Haak, Monika Kellerer, Erhard G. Siegel · 2026 · Diabetologie und Stoffwechsel
SGLT2 Inhibitors Reduce Heart Failure Hospitalization, Cardiovascular Death and Kidney Outcomes in Type 2 Diabetes: A Meta‐Analysis of Randomized Controlled Trials
Ahmed Elbataa, Ahmed Mansour, Ahmed Elazab, Ammer Alabed, Rotana Jawed Masood, Afaf F Albogami, Jomanah Abdulwahab Alsalami, Ahmed Owais Hafeezallah, Khalid Mohammed Alzahrani, Khalid fares Alotaibi et al. · 2026 · Diabetes Obesity and Metabolism
Blood-based biomarkers and major adverse cardiac events after percutaneous coronary intervention: a systematic review with narrative synthesis
Shyamalendu Tripathy, Minesh Patel · 2026 · Frontiers in Cardiovascular Medicine
Gene‐Guided Therapy in Type 2 Diabetes Mellitus: An Integrative Review of the Pharmacogenetics of Metformin and Sodium‐Glucose Cotransporter‐2 Inhibitors
Imran Hossain, Mahnoor Haidar, Mahfuj Ahmed Ratul, Jannatul Ferdous, Sraboni Shabnaz, Abul Fojal Nokib, Fatema Tuz Zohora · 2026 · Endocrinology Diabetes & Metabolism
Fracture risk associated with sodium-glucose cotransporter-2 inhibitors in adults with type 2 diabetes, chronic kidney disease, or heart failure: an updated systematic review and meta-analysis of randomized controlled trials
Ruiheng Zhang, Wei Li · 2026 · Research Square
Pharmacotherapy for MASLD/MASH: approved therapies, drug repurposing, and emerging mechanism-based candidates
Majid Mufaqam Syed‐Abdul · 2026 · Expert Opinion on Pharmacotherapy
Dapagliflozin and 54-week kidney function in kidney transplant recipients with post-transplant diabetes mellitus: a randomized controlled trial
Jinghui Li, Zhirong Fu, Rongkun Xu, Yanqian Zhuang, Pin Chen, 陈晶波 · 2026 · Diabetes Research and Clinical Practice
Comparative Effectiveness and Reliability of SGLT2 Inhibitors with Metformin in patients with Inadequate control of NIDDM
S. Brigida, Arul Amutha Elizabeth, Soujania Singh · 2026 · Research Journal of Pharmacy and Technology
Cardiovascular Outcomes Across the Sodium-Glucose Cotransporter (SGLT) Selectivity Spectrum in Type 2 Diabetes and Chronic Kidney Disease: A Systematic Review of Heart Failure, Myocardial Infarction, and Stroke
Mbony Joshua Cho, Aakash Hans, Aftab Ali, Surksha Gul, Vishal Bhatia, Achu Fonkem · 2026 · Cureus
Health-System and Sex Differences in Cardioprotective Diabetes Therapy Among Adults With Type 2 Diabetes and Established ASCVD: A Two-Center EHR Study
Chetan Pavuluri, Aditi Rao, Evan Sholle, Xiaoyue Ma, Rakesh Gullapelli, Khurram Nasir, Archana Sadhu, Eleonora Avenatti, Sangeeta Kashyap · 2026 · Research Square
Gliflozins in the treatment of diabetes and its complications
Petr Žák, Karolína Kvíčalová, Eliška Ambrožová · 2026 · Klinická farmakologie a farmacie
Towards precision medicine in diabetes: pharmacogenomic approaches for MODY and type 2 diabetes with insights from GLIS3 gene variants
Abhisheka Lenin, Jasmin Sajini Rajayan · 2026 · Frontiers in Endocrinology
Factors Associated With SGLT2 Inhibitor Initiation in Newly Diagnosed Type 2 Diabetes: A Real‐World Analysis From German Primary Care
Karel Kostev, Beate Leppert, Maximilian Peters · 2026 · Diabetes Obesity and Metabolism
Type 2 diabetes medications and their implications for cancer treatment: A comprehensive review
Neda Shakour, Fatemeh Hosseini, Zahra Esmaeili, Farzin Hadizadeh · 2026 · Molecular Aspects of Medicine
Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes
Farkouh, Michael E., Domanski, Michael, Dangas, George D., Godoy, Lucas C., Mack, Michael J., Siami, Flora S., Hamza, Taye H., Shah, Binita, Stefanini, Giulio G., Sidhu, Mandeep S. et al. · 2019 · Journal of the American College of Cardiology